Emergent BioSolutions CEO Reports That Johnson & Johnson Vaccine Production Could Resume Within Days
Emergent BioSolutions could resume manufacturing Johnson & Johnson’s Covid-19 vaccine within days, CEO Robert Kramer told a House panel Wednesday.
The Food and Drug Administration ordered Emergent to pause production last month after a series of manufacturing problems at its Baltimore plant, one of which led to the contamination of 15 million J&J doses with ingredients from a Covid-19 vaccine made by AstraZeneca. The federal government directed AstraZeneca to find a new production partner after the mix-up.
“We have made significant progress” on a range of problems cited by FDA in April, including unsanitary conditions and congested facilities, Kramer told the House Coronavirus Crisis Subcommittee. “We are very close to completing them and now expect we’ll be in a position to resume production within a matter of days.”
